FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNeuren Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NEU.AX
Neuren Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Neuren Pharmaceuticals Limited (NEU.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNEU.AX
NEU.AX
Neuren Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NEU.AX
  1. Home
  2. Stocks
  3. Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited

🇦🇺NEU.AX•ASX

Neuren Pharmaceuticals Limited

🇦🇺NEU.AX•ASX
P/E ratio
139.67

Your view on NEU.AX

P/E
139.67
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Neuren Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Jonathan Charles Pilcher
Headquarters
117 Camberwell Road, Hawthorn East, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Jonathan Charles Pilcher
Headquarters
117 Camberwell Road, Hawthorn East, VIC, AU
Description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.

The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome.

The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Neuren Pharmaceuticals Limited from FRC's valuation model, read against the market price. NEU.AX last traded at AUD 22.72, 139.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Neuren Pharmaceuticals Limited. Starting points for Neuren Pharmaceuticals Limited: P/E 139.7, EPS AUD 0.16, beta 1.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Neuren Pharmaceuticals Limited. Trailing twelve-month EPS for Neuren Pharmaceuticals Limited stands at AUD 0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterJun 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateAUD 0.37AUD 0.23AUD 0.41AUD 0.58
Lowest estimateAUD 0.37AUD 0.23AUD 0.37AUD 0.53
Highest estimateAUD 0.37AUD 0.23AUD 0.45AUD 0.71
Number of analysts1144
A year agoAUD 1.03AUD 0.12AUD 0.231—
Growth vs a year ago−63.9%+96.8%——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterJun 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateAUD 94.17MAUD 45.40MAUD 132.23MAUD 178.57M
Lowest estimateAUD 94.17MAUD 45.40MAUD 129.13MAUD 172.17M
Highest estimateAUD 94.17MAUD 45.40MAUD 138.82MAUD 186.01M
Number of analysts1144
A year agoAUD 192.50MAUD 28.28MAUD 64.63M—
Growth vs a year ago−51.1%+60.6%+104.6%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NEU.AX20 companies · 8 funds
Compare NEU.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACW.AXActinogen Medical LimitedHealthcareBiotechnology—
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
ATH.AXAlterity Therapeutics LimitedHealthcareBiotechnology—
ENP.AXEntropy Neurodynamics LimitedHealthcareBiotechnology—
IXC.AXInvex Therapeutics LtdHealthcareBiotechnology—
NSB.AXNeuroScientific Biopharmaceuticals LimitedHealthcareBiotechnology—
NUZ.AXNeurizon Therapeutics LimitedHealthcareBiotechnology—
NYR.AXNyrada Inc.HealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ORMPOramed Pharmaceuticals Inc.HealthcareNASDAQ$169.2M
ORPOFOSE Immunotherapeutics S.A.HealthcareOTC$260.3M
ORYZFOryzon Genomics S.A.HealthcareOTC$283.9M
OSRHWOSR Holdings, Inc.HealthcareNASDAQ$7.8M
OSTXOS Therapies IncorporatedHealthcareAMEX$48.1M
OTLCOncotelic Therapeutics, Inc.HealthcareOTC$21.2M
OTLKOutlook Therapeutics, Inc.HealthcareNASDAQ$99.3M
OVIDOvid Therapeutics Inc.HealthcareNASDAQ$426.5M
OXBOFOxford BioDynamics PlcHealthcareOTC$4.3M
OZYMFStrategic Partners A/SHealthcareOTC$3.7M
PAB.AXPatrys LimitedHealthcareASX—
PALIPalisade Bio, Inc.HealthcareNASDAQ$168.9M
ETFs holding Neuren Pharmaceuticals Limited
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.00%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.00%
IEFAiShares Core MSCI EAFE ETF$188.8B in assets0.01%
AVDVAvantis International Small Cap Value ETF$19.2B in assets0.05%
ISCFiShares International Small-Cap Equity Factor ETF$717M in assets0.12%
AVDSAvantis International Small Cap Equity ETF$379M in assets0.07%
DFISDimensional - International Small Cap ETF$5.8B in assets0.04%
DLSWisdomTree International SmallCap Dividend Fund$1.0B in assets0.04%

Largest holders first, then the funds most concentrated in NEU.AX.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Neuren Pharmaceuticals Limited. Coverage tracks Neuren Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Neuren Pharmaceuticals Limited.

NEU.AX AnalysisGood
Past
3
Growth
5
Health
5
Profit
2
Value
1